Bepi Dispenser Launches €800K Crowdfunding to Revolutionize Hospital Drug Administration

The equity crowdfunding round for Bepi Dispenser, supported by Over Ventures, aims to raise 800,000 euros. It is aimed at completing the industrialization activities, carrying out the necessary tests in the operational field (hospital), launching series production with the purchase of molds for the custom-designed components, increasing the workforce and promoting the launch on the Italian and international markets.

In the last two years, the company has raised another 800,000 euros in a private round and participated in the acceleration program “Silver Accelerator”, 75% funded by CDP Venture.

The automatic dispenser by Bepi Dispenser for hospital patients

The device has a capacity of 60 pills, enough to manage the therapy for the entire duration of the hospital stay for most patients and allows the addition or modification of medications in real time. At the preset time, Bepi automatically dispenses the prescribed dose, alerting the patient with light and sound signals.

The dispenser is configured by importing medical prescriptions from the patient’s electronic medical record or via a dedicated tablet and only authorized personnel can load the pills, thanks to a protected and tracked access system.

Integration with electronic medical records used in healthcare facilities allows for centralized and automated management of therapies.

A system created to address the shortcomings of the nursing system

Bepi Dispenser was designed and developed entirely in Italy by a team with over twenty years of experience in the healthcare, technological and managerial fields.

It was born from the need to address the shortcomings of the nursing system of the most advanced countries, identifying an automated solution to improve the efficiency of drug administration.

A study published in the scientific journal “The Lancet”, in fact, has highlighted how exceeding the ratio of 5 patients for each nurse, mortality and length of hospital stay progressively increase.

In Europe and Italy, where the situation is critical from this point of view, the number of patients per nurse frequently exceeds 12, with increases in mortality and complications of up to 50% and in the length of hospital stay of 20%.

The business model and next steps

Bepi’s business model, for which two patents have been filed and are in the process of being released, is based on the association between the dispenser and the patient via a bracelet, while the machine is provided on loan for use, with invoicing calculated on the actual use, i.e. on the individual patient.

By the beginning of the summer, the distribution of the pre-series with first prototypes will begin at some hospitals.

The company has also already signed letters of commitment with seven healthcare facilities in Northern Italy, is in the process of defining distribution agreements with leading hospitals and is expecting to make profits and achieve financial independence in the first half of 2026.

“In addition to the EU market, we are also targeting the US and Arab markets, where we have already developed contacts and received requests,” says Roberto Schibuola , CEO and co-founder of Bepi, together with Nicola Abbattista, Marco Scardino and Francesco Tasso , the latter two respectively head of anesthesia and anesthetist at leading hospital facilities in Italy.

__

(Featured image by James Yarema via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Crowdfunding buzz. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.